{"listing":{"listing_type":"product","name":"Danegaptide","slug":"danegaptide","tagline":"Oral small-molecule candidate for diabetic retinopathy","description":"Danegaptide is Breye Therapeutics' lead orally administered small-molecule drug candidate for early retinal disease, including non-proliferative diabetic retinopathy. The company has reported completion of a Phase 1b trial and plans a randomized Phase 2 clinical proof-of-concept study starting in 2027.","url":"https://breye.com/","is_stealth":false,"normalized_domain":"breye.com","normalized_url_key":"breye.com","parent_slug":"breye-therapeutics","parent":{"slug":"breye-therapeutics","name":"Breye Therapeutics","listing_type":"company","profile_url":"/companies/breye-therapeutics"},"type_data":{},"logo":"https://breye.com/wp-content/uploads/2025/06/breye-favicon_s.png","links":[],"entry_points":[{"kind":"homepage","url":"https://breye.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://breye.com/","audience":"human","primary":true,"listed_by":"community","on_listing_domain":true},"agent":null},"founders":[],"media":{"logo_asset_id":"9ff7d618-56a7-408d-9c7c-e8d669229461"},"categories":["Biotech","Healthcare"],"stage":null,"founded_year":null,"location":null,"pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-10-02T20:25:32.320Z","added_via":"web","geo":null,"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-10-02T20:25:32.320Z","is_featured":false,"category_memberships":[{"kind":"product_category","slug":"biotech","name":"Biotech","note":null,"profile_url":"/categories/biotech"},{"kind":"product_category","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/categories/healthcare"}]}}